Abstract
Cyclic di-GMP (CDG) was applied to MUC1 glycopeptide-based cancer vaccines with physical mixing and built-in (at 2'-OH of CDG) strategies for activating the STING pathway. CDG in both strategies behaved as a potent immunostimulant and contributed to high titers of IgG antibodies and the expression of multiple cytokines.
MeSH terms
-
Adjuvants, Immunologic / chemical synthesis
-
Amino Acid Sequence
-
Animals
-
B7-2 Antigen / immunology
-
Cancer Vaccines / immunology*
-
Cancer Vaccines / pharmacology
-
Cyclic GMP / analogs & derivatives*
-
Cyclic GMP / chemical synthesis
-
Cyclic GMP / immunology
-
Cytokines / metabolism
-
Female
-
Glycopeptides / chemical synthesis
-
Glycopeptides / immunology*
-
Humans
-
Immunity, Cellular / drug effects
-
Immunity, Humoral / drug effects
-
Immunoglobulin G / metabolism
-
Immunoglobulin M / metabolism
-
MCF-7 Cells / immunology
-
Macrophage Activation / drug effects
-
Membrane Proteins / agonists
-
Membrane Proteins / metabolism*
-
Mice
-
Mice, Inbred BALB C
-
Mucin-1 / immunology
-
Peptide Fragments / chemical synthesis
-
Peptide Fragments / immunology
-
RAW 264.7 Cells / immunology
-
Signal Transduction / drug effects
Substances
-
Adjuvants, Immunologic
-
B7-2 Antigen
-
Cancer Vaccines
-
Cd86 protein, mouse
-
Cytokines
-
Glycopeptides
-
Immunoglobulin G
-
Immunoglobulin M
-
MUC1 protein, human
-
Membrane Proteins
-
Mucin-1
-
Peptide Fragments
-
STING1 protein, human
-
Sting1 protein, mouse
-
bis(3',5')-cyclic diguanylic acid
-
Cyclic GMP